Jefferies and Piper Sandler are acting as joint book-running managers for the proposed offering.

The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid ...

THE WOODLANDS, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company has made the strategic decision to eliminate its commercial ...

THE WOODLANDS, Texas, June 23, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) (Nasdaq: LXRX) today announced plans to advance its investigational drug LX9211 into late-stage development ...

“We are implementing a strategic realignment of Lexicon around some truly compelling assets, with a focus on LX9211 for neuropathic pain and other early-stage research and development programs,” said ...

THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the successful completion of the ...

THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, ...

As of Wednesday, January 28, Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 7.60%, which has investors ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, today updated its drug development progress and reported ...

INVUS TO INVEST $205 MILLION IN COMMON STOCK AT SIGNIFICANT PREMIUM SYMPHONY TO FUND ADDITIONAL $60 MILLION TO ADVANCE FIRST THREE DRUGS THE WOODLANDS, Texas, June 17 ...